M. Clerici

3.4k total citations · 1 hit paper
33 papers, 2.1k citations indexed

About

M. Clerici is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, M. Clerici has authored 33 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 9 papers in Molecular Biology. Recurrent topics in M. Clerici's work include Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Research Studies (11 papers) and Cancer Treatment and Pharmacology (6 papers). M. Clerici is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Research Studies (11 papers) and Cancer Treatment and Pharmacology (6 papers). M. Clerici collaborates with scholars based in Italy, Malaysia and Denmark. M. Clerici's co-authors include M. Marangolo, Lucio Crinò, G Luporini, Maurizio Tonato, Filippo de Marinis, Vincenzo Adamo, Giorgio V. Scagliotti, Giuseppe Altavilla, Francesco Di Costanzo and C. Boni and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

M. Clerici

32 papers receiving 2.0k citations

Hit Papers

Phase III Randomized Trial Comparing Three Platinum-Based... 2002 2026 2010 2018 2002 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer
    2002 739 citations Giorgio V. Scagliotti, Filippo de Marinis et al. Journal of Clinical Oncology profile →

Peers

M. Clerici
Dusan Kotasek Australia
Michael Fanucchi United States
Raffaella Palumbo Italy
Nobukazu Fujimoto Japan
R. C. Newland Australia
G Brufman Israel
W P Tong United States
A Mussi Italy
G. Steger Austria
Edward Greeno United States
Dusan Kotasek Australia
M. Clerici
Citations per year, relative to M. Clerici M. Clerici (= 1×) peers Dusan Kotasek

Countries citing papers authored by M. Clerici

Since Specialization
Citations

This map shows the geographic impact of M. Clerici's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Clerici with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Clerici more than expected).

Fields of papers citing papers by M. Clerici

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Clerici. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Clerici. The network helps show where M. Clerici may publish in the future.

Co-authorship network of co-authors of M. Clerici

This figure shows the co-authorship network connecting the top 25 collaborators of M. Clerici. A scholar is included among the top collaborators of M. Clerici based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Clerici. M. Clerici is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mandalà, Mario, Federica Grosso, Roberta Sanfilippo, et al.. (2012). Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies. British Journal of Cancer. 107(4). 612–616. 3 indexed citations
2.
3.
Labianca, Roberto, Mario Mandalà, & M. Clerici. (2008). [Clinical role of palonosetron for patients receiving cisplatin-based chemotherapy].. PubMed. 94(2). suppl 23–5. 1 indexed citations
4.
Correale, Pierpaolo, Daniela Cerretani, M. Clerici, et al.. (2004). Gemcitabine (GEM), 5-Fluorouracil (5-FU) and Folinic Acid (FA) in Patients with Different Gastroenteric Malignancies. Journal of Chemotherapy. 16(2). 206–210. 4 indexed citations
5.
Crinò, Lucio, Giorgio V. Scagliotti, M. Marangolo, et al.. (1997). Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.. Journal of Clinical Oncology. 15(1). 297–303. 268 indexed citations
6.
Piazza, E., et al.. (1997). 138 Gemcitabine in the treatment of pretreated metastatic non small cell lung cancer: A preliminary report. Lung Cancer. 18. 38–38. 2 indexed citations
7.
Tedeschi, L., et al.. (1996). Cisplatin-associated anaemia in patients with solid tumours. Supportive Care in Cancer. 4(3). 218–219. 4 indexed citations
8.
9.
Tedeschi, L., et al.. (1995). 250 Evaluation of incidence of cisplatin (CDDP)—anemia developed in three subsets of neoplastic patients (PTS). European Journal of Cancer. 31. S55–S55. 3 indexed citations
10.
Clerici, M., Valter Torri, Fulvia Colombo, et al.. (1994). Patterns of Care and Survival in Non Small Cell Lung Cancer: 15 Years’ Experience in a General Hospital. Tumori Journal. 80(2). 106–112. 7 indexed citations
11.
12.
Cesana, Bruno Mario, et al.. (1993). A Cisplatinum- Cyclophosphamide Regimen in Advanced Ovarian Cancer: Reporting 5-Year Results. Oncology. 50(2). 92–99. 1 indexed citations
13.
14.
Pastorino, Ugo, Maurizio Infante, M. Maioli, et al.. (1993). Adjuvant treatment of stage I lung cancer with high-dose vitamin A.. Journal of Clinical Oncology. 11(7). 1216–1222. 263 indexed citations
15.
Pastorino, Ugo, Giuseppe Chiesa, Maurizio Infante, et al.. (1991). Safety of High-Dose Vitamin A. Oncology. 48(2). 131–137. 28 indexed citations
16.
Monfardini, S., Emanuela Vaccher, Giorgio Pizzocaro, et al.. (1989). Unusual malignant tumours in 49 patients with HIV infection. AIDS. 3(7). 449–452. 106 indexed citations
17.
Clerici, M., Anna Maria Lavezzi, C. Vergani, et al.. (1989). Cytogenetic Analysis in 28 Radically Operated Non-Small-Cell Lung Cancer: Preliminary Considerations. Tumori Journal. 75(5). 483–485. 4 indexed citations
18.
Brambilla, L., et al.. (1988). Oral Etoposide for Kaposi’s Mediterranean Sarcoma. Dermatology. 177(6). 365–369. 15 indexed citations
19.
Pastorino, Ugo, E. Soresi, M. Clerici, et al.. (1988). Lung Cancer Chemoprevention with Retinol Palmitate: Preliminary data from a randomized trial on stage la non small-cell lung cancer. Acta Oncologica. 27(6). 773–782. 16 indexed citations
20.
Labianca, Roberto, et al.. (1988). Cisplatin + 5-fluorouracil versus 5-fluorouracil alone in advanced colorectal cancer: a randomized study. European Journal of Cancer and Clinical Oncology. 24(10). 1579–1581. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dusan Kotasek Breakdown of academic impact, for papers by Michael Fanucchi Breakdown of academic impact, for papers by Raffaella Palumbo Breakdown of academic impact, for papers by Nobukazu Fujimoto Breakdown of academic impact, for papers by R. C. Newland Breakdown of academic impact, for papers by G Brufman Breakdown of academic impact, for papers by W P Tong Breakdown of academic impact, for papers by A Mussi Breakdown of academic impact, for papers by G. Steger Breakdown of academic impact, for papers by Edward Greeno
Rankless by CCL
2026